Literature DB >> 12587181

50 Years with lithium treatment in affective disorders: present problems and priorities.

P Vestergaard1, R W Licht.   

Abstract

Lithium has been used as a treatment for various psychiatric- and somatic-illnesses for more than 50 years. Today the main use of lithium is for the prevention of episode recurrences in bipolar disorder. The main emphasis of this review will be on the efficacy and effectiveness of lithium prophylaxis in bipolar disorder but the review will also discuss other indications for lithium treatment, the historical development, pharmacokinetic and -dynamic issues, unwanted effects of lithium and the organisation of treatment services. Finally, although not the main purpose of this review, a short description of alternative mood stabilizing drugs will also be presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12587181     DOI: 10.3109/15622970109039980

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  4 in total

Review 1.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.

Authors:  J R Woodgett
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

2.  Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus.

Authors:  Nihat Aksakal; Candaş Erçetin; Beyza Özçınar; Ferihan Aral; Yeşim Erbil
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

3.  Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate.

Authors:  Ren H Wu; Tina O'Donnell; Michele Ulrich; Sheila J Asghar; Christopher C Hanstock; Peter H Silverstone
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-07-30

4.  Perspectives, attitude, and practice of lithium prescription among psychiatrists in India.

Authors:  Sucharita Mandal; Spoorthy Sai Mamidipalli; Bhaskar Mukherjee; Suchandra K Hari Hara
Journal:  Indian J Psychiatry       Date:  2019 Sep-Oct       Impact factor: 1.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.